Pharming Group NV (NASDAQ:PHAR) — Market Cap & Net Worth
Market Cap & Net Worth: Pharming Group NV (PHAR)
Pharming Group NV (NASDAQ:PHAR) has a market capitalization of $745.10 Million ($745.10 Million) as of September 16, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #10240 globally and #2754 in its home market, demonstrating a -6.06% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Pharming Group NV's stock price $10.55 by its total outstanding shares 70625230 (70.63 Million). Also see PHAR total assets for a full breakdown of the balance sheet.
Pharming Group NV Market Cap History: 2020 to 2026
Pharming Group NV's market capitalization history from 2020 to 2026. Data shows change from $1.07 Billion to $745.10 Million (-7.70% CAGR). Also see cash efficiency ratio of Pharming Group NV for how efficiently the company converts equity into cash flow.
Index Memberships
Pharming Group NV is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.03% | #290 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1065 of 3165 |
Weight: Pharming Group NV's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Pharming Group NV Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Pharming Group NV's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Pharming Group NV (PHAR) share price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
3.31x
Pharming Group NV's market cap is 3.31 times its annual revenue
Latest Price to Earnings (P/E) Ratio
436.51x
Pharming Group NV's market cap is 436.51 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $1.07 Billion | $212.17 Million | $37.75 Million | 5.06x | 28.43x |
| 2021 | $631.39 Million | $198.87 Million | $16.00 Million | 3.17x | 39.47x |
| 2022 | $779.00 Million | $205.62 Million | $13.67 Million | 3.79x | 56.97x |
| 2023 | $807.25 Million | $245.32 Million | -$10.55 Million | 3.29x | N/A |
| 2024 | $710.84 Million | $297.20 Million | -$11.84 Million | 2.39x | N/A |
| 2025 | $1.25 Billion | $377.18 Million | $2.86 Million | 3.31x | 436.51x |
Competitor Companies of PHAR by Market Capitalization
Companies near Pharming Group NV in the global market cap rankings as of September 16, 2026. Review PHAR goodwill-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Pharming Group NV by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Pharming Group NV Historical Marketcap From 2020 to 2026
Between 2020 and today, Pharming Group NV's market cap moved from $1.07 Billion to $ 745.10 Million, with a yearly change of -7.70%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $745.10 Million | -40.29% |
| 2025 | $1.25 Billion | +75.56% |
| 2024 | $710.84 Million | -11.94% |
| 2023 | $807.25 Million | +3.63% |
| 2022 | $779.00 Million | +23.38% |
| 2021 | $631.39 Million | -41.16% |
| 2020 | $1.07 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Pharming Group NV was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $745.10 Million USD |
| MoneyControl | $745.10 Million USD |
| MarketWatch | $745.10 Million USD |
| marketcap.company | $745.10 Million USD |
| Reuters | $745.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company's lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE… Read more